Abstract
The research focused on identifying new methods for treating breast cancer, one of the most common cancers in women. Benserazide, benitrobenrazide, and their derivatives were tested on two cancer cell lines (MCF-7 and MDA-MB-231). Their ability to inhibit cancer cell growth and synergize with doxorubicin was evaluated. The results showed that the compounds effectively suppressed cancer cell proliferation, particularly at low concentrations, and enhanced doxorubicin's effects. The main mechanisms of action included inhibition of hexokinase II, a key enzyme in cancer cell metabolism, and induction of apoptosis and autophagy. These findings may contribute to the development of more effective and safer cancer therapies.